Kornimate/medical-research-clean huggingface dataset:
effects of propofol-induced anaesthesia on the st-segment of the ecg

Conditions: No Specific Condition (Patients Without Brugada Syndrome)

Summary: the purpose of this study is to assess the effect of propofol induced general anaesthesia on the st-segment of the electrocardiogram. this will be realised by retrospectively analysing the ecg-recordings from adult patients undergoing any treatment at the catheterisation laboratory. the st-segment and other ecg measurements from induction of anaesthesia up to 20 minutes later, will be assessed and compared to the baseline values of the respective segments acquired before injecting propofol. it is essential in this study to exclude any patients burdened with the diagnosis, suspicion or family history of brugada syndrome.


Eligibility criteria:
inclusion criteria: * induction of anaesthesia with propofol * monitored anaesthesia in the cathlab of the universitair ziekenhuis brussel exclusion criteria: * brugada syndrome or family history of brugada syndrome * paediatric population (age \<18) * patients who did not receive propofol during the procedure * patients who presented with fever (central core temperature \>38,0°c)
siewert type ii esophageal adenocarcinoma: relationship between histology and survival

Conditions: Siewert Type II Adenocarcinoma of Esophagogastric Junction

Summary: in siewert type ii adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.

in order to achieve further data on the biological patterns of intestinal and diffuse subtypes of esophageal adenocarcinoma (lauren's classification), on the frequency of gastric greater curvature nodal stations and on the clinical relevance, in terms of prognosis and survival, of these parameters, a siewert type ii case series of siewert type ii adenocarcinomas, submitted to primary (no neoadjuvant therapy) surgical, studied, operated upon and followed up, were analysed. according to histologic patterns, cases were ordered in intestinal and diffuse adenocarcinoma sub types (lauren's classification)and distinguished in barret's, cardiopyloric, gastric types.

Eligibility criteria:
inclusion criteria: siewert type ii adenocarcinoma \> 18 year submitted to primary surgery exclusion criteria: siewert type ii adenocarcinoma submitted to neoadjuvant therapy. siewert type i adenocarcinoma. siewert type iii adenocarcinoma squamous carcinoma -

Keywords: esophageal cancer adenocarcinoma of the esophagus esophageal surgery
the rosuvastatin in transplant recipients study

Conditions: Disorder Related to Renal Transplantation; Hypercholesterolemia

Summary: renal transplant recipients need life long immunosuppression and one of the new drugs is everolimus. everolimus is a potent immunosuppressive drug and one of the main side-effects are increased blood cholesterol levels. many renal transplant recipients are treated with a cholesterol lowering agent, mainly fluvastatin. rosuvastatin is a new cholesterol lowering drug on the market with a potential higher cholesterol lowering potency. in the present study the investigators will examine the hypothesis that rosuvastatin reduce cholesterol levels more than fluvastatin in renal transplant patients.


Eligibility criteria:
inclusion criteria: * renal transplant recipients with stable renal function (plasma creatinine \< 200 µmol/l) * renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion * \> 18 years of age * male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs * signed informed consent exclusion criteria: * patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not * patients with a known hypersensitivity to rosuvastatin * change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study \[e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs\] * pregnant or nursing mothers

Keywords: immunosuppression everolimus rosuvastatin fluvastatin lipid lowering
impact of physical activity and diet on symptom experience in people living with hiv

Conditions: HIV/AIDS

Summary: we will conduct a four-year, observational study of 850 participants to measure physical activity and diet, once a year for three years. all participants will also complete the standard centers for aids research (cfar) network of integrated clinical systems (cnics) patient-reported outcomes (pro) and clinical assessment procedures. an enhanced pro assessment (consisting measures of physical activity, diet intake and anthropomorphic factors) will be included after the routine patient clinic visit at four cnics sites: case western reserve university, university of alabama at birmingham, university of washington, and fenway health.

prosper-hiv is a four-year, prospective, observational study of 850 cnics participants who will complete an enhanced patient-reported outcome (pro) assessment to measure physical activity and diet intake, once a year for three years. all participants will also complete the standard cnics pro and clinical assessment procedures. we propose to integrate the following measures, physical activity (triaxial accelerometery), dietary intake (24-hour diet recalls), and anthropomorphic factors (waist-hip-ratio), into an enhanced annual assessment of patient reported outcomes at four cnics sites: case western reserve university, university of alabama at birmingham, university of washington, and fenway health. our four primary objectives are to: 1. identify and characterize longitudinal, objectively measured, physical activity and dietary patterns among plhiv 2. examine the relationship between objectively-measured physical activity and self-reported physical activity on the lipid research clinics physical activity questionnaire. 3. determine which aspects of physical activity patterns and diet quality are associated with decreased symptom burden and intensity in plhiv, and if this relationship is moderated by age and sex. 4. explore the potential mediating effect of anthropomorphic and physical fitness variables on the relationships between physical activity, dietary patterns, and symptom burden and intensity in plhiv. we hypothesize that people living with hiv who 1) have more intense, frequent and longer physical activity bouts will have age- and sex-dependent reduced symptom burden; 2) eat better quality diets (e.g., more fiber and protein, fewer carbohydrates) will have reduced symptom burden and intensity and that this relationship will also vary by age and sex.

Eligibility criteria:
inclusion criteria: 1. be an active cnics participant 2. aged ≥18 years 3. prescribed hiv antiretroviral therapy, and 4. have an undetectable hiv viral load: defined as the most recent hiv viral load \<200 copies/ml, checked within the past year. exclusion criteria: 1) did not complete the hiv symptom index in the pro assessment (2) no reliable access to a telephone or internet-enable telephone services needed to complete the 24-diet recalls (3) was pregnant, breast-feeding, or planning a pregnancy at the time of pro assessment (4) planning to move out of the area in the next 36 months, or (5) non-english speaking.
a self-guided app-based virtual reality cognitive behavior therapy for anxiety disorder in children

Conditions: Anxiety Disorders

Summary: to examine the efficacy of a fully self-guided app-based virtual reality cognitive behavior therapy (vr cbt) using low-cost (cardboard) virtual reality goggles compared with a wait-list control group and to determine its user friendliness. we hypothesize that children with gad enrolled in the self-guided app will present lower scores of anxiety.

a randomized controlled design will be carried out, in which the effectiveness and user- friendliness of an online app-based vr self-help treatment '0-anxiety' will be evaluated. our primary objective is to determine the clinical effects (a reduction in anxiety symptoms at post-test \[between the experimental condition and controls\] of 0-anxiety, and whether effects are sustainable at follow-up \[a reduction in anxiety symptoms between baseline and follow-up for those in the experimental condition\]). our secondary objective is to determine the user-friendliness of 0-anxiety. in this study, 230 children from the brazilian population will be randomized over 2 conditions: the experimental condition (0-anxiety) and a waitlist condition. the duration of the intervention will be 3 weeks. measures will be taken at baseline, directly after the intervention (3 weeks) and at 3 months (follow-up). all measures will be completed online. therefore, the child will participate in the study in his/her natural environment. subjects in the wait-list condition will receive the intervention after completion of the post-test. randomization (block-randomization) will be performed by an independent researcher.

Eligibility criteria:
inclusion criteria: * individuals must be between 8-12 years old; * subjects must score above 25 on the scared questionnaire; * subjects must have access to a smart phone and internet; * individuals must be willing to participate in the research study and providing informed consent. exclusion criteria: * children that present with symptoms of severe depression or suicidality as measured with ksads-pl26; * children that have insufficient knowledge of the portuguese language; * subjects that are under any current treatment for anxiety disorder or using psychotropic medication.

Keywords: anxiety virtual reality app self-guided cognitive behavior therapy
pharmacokinetics and safety study of omecamtiv mecarbil in healthy japanese adults

Conditions: Healthy Volunteer

Summary: the purpose of this study is to evaluate the pharmacokinetics (pk), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in japan.

this study was conducted by amgen as the ind holder, with cytokinetics as a collaborator. due to the termination of the collaboration agreement between amgen and cytokinetics in may 2021 and subsequent transfer of the omecamtiv mecarbil ind from amgen to cytokinetics, cytokinetics is now listed as the sponsor.

Eligibility criteria:
inclusion criteria: * no history or evidence of clinically relevant medical disorders as determined by the investigator, and in good health as determined by a pre-study physical examination and medical history with no clinically significant abnormalities, normal vital signs and no history or presence of a clinically significant abnormal electrocardiogram finding * subjects' pre-study clinical laboratory findings (including creatine phosphokinase) should be within normal range or if outside of the normal range, are deemed not clinically significant by the investigator. exclusion criteria: * a clinically significant disorder/disease, including gastro intestinal abnormalities that might interfere with absorption * an unstable medical condition, defined as having been hospitalized within 28 days before day 1, major surgery within 6 months before day 1, or otherwise unstable in the judgment of the investigator * history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or medical monitor would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion * history of malignancy of any type other than surgically excised non-melanomatous skin cancers or in situ cervical cancer within 5 years before the day of dosing * use of any prescription or over-the-counter medications within 14 days or 5 half-lives (whichever time period is greater), prior to receiving the first dose of omecamtiv mecarbil (acetaminophen up to 2 grams per day for analgesia and hormone replacement therapy (e.g., estrogen) will be allowed * use of any known inhibitors of cyp3a4/p-glycoprotein (p-gp) or cyp2d6 within 14 days or 5 half-lives, whichever is longer; or use of grapefruit juice or grapefruit containing products within 7 days prior to receiving the first dose of omecamtiv mecarbil * use of any known cyp3a4 inducers within 30 days or 5 half-lives, whichever is longer, before receiving omecamtiv mecarbil

Keywords: heart failure
collect clinical data in chinese patients received cubicin treatment for actual usage in clinical practice

Conditions: S. Aureus Bloodstream Infection

Summary: this is a multicenter, observational, non-interventional registry designed to collect clinical data in chinese patients who have received cubicin treatment under condition of actual usage in clinical practice.

mc md

Eligibility criteria:
inclusion criteria: * patient has received cubicin treatment, decided by treating physician * a patient who is considered as ethnic chinese * provision of subject informed consent exclusion criteria: * a patient record will not be eligible for the registry database if the patient received cubicin as part of a controlled clinical study for the current infection episode.

Keywords: safety efficacy chinese patients practice
a quality improvement project to assess and refine the handover process at morning trauma meetings

Conditions: Neck of Femur Fracture; Fractures, Bone; Orthopedic Disorder

Summary: this project was intended to observe the handover of trauma and orthopaedic patients at a district general hospital in the uk. following the implementation of a standard operating protocol, the handover of patient information improved including neck of femur fracture patients significantly. the study can therefore be utilised by other similarly structured departments to improve the handover process, thereby improving patient safety.

poor handover and inadequate transmission of clinical information between shifts can result in patient harm. this study was designed to evaluate the impact of implementing a handover protocol on the quality of information exchanged in the trauma handover meetings in a uk hospital. a prospective single centre observational study was performed at an acute nhs trust, using the plan-do-study-act (pdsa) methodology. ten consecutive weekday trauma meetings, involving 43 patients, were observed to identify poor practices in handover. this data was used in conjunction with the royal college of surgeon's recommendations for effective handover (2007) to create a standard operating protocol (sop). following the implementation of the sop, a further 8 consecutive weekday trauma meetings, involving a further 47 patients, were observed. the data collection was performed by 5 trained independent observers. the data was analysed using t test for quantitative variables and chi-square or fisher's exact tests for categorical variables.

Eligibility criteria:
inclusion criteria: * all patients that were handed over were included in the study. exclusion criteria: * nil.
using the hierarchical cluster method for foot deformities

Conditions: Foot Deformities

Summary: the aim of this study is to analyze all of the variables with a hierarchical cluster analysis of multivariate statistical methods to obtain more sensitive results, and also to add a new dimension to the hypothesis included in the study.

aim and introduction: due to individual anthropometric differences, there are many different types of foot posture foot posture variations affect lower extremity structure, alignment and biomechanical characteristics. particularly in younger people, performing critical biomechanical measurements in the lower extremity and foot is extremely important to the detection of, and early intervention in, orthopedic problems that these individuals will encounter in their later life. in the literature, attempts at analysis of the evaluations realized so far have been made by univariate analysis. considering the relationship between variation and variables, these methods result in loss of information. the aim of this study is to analyze all of the variables with a hierarchical cluster analysis of multivariate statistical methods to obtain more sensitive results, and also to add a new dimension to the hypothesis included in the study. methods: the study is carried out on 2nd and 3rd year university students in the physiotherapy and rehabilitation department taking a kinesiology course. the analyses are performed at the biruni university physiotherapy and rehabilitation laboratory. patients with musculoskeletal system pathomechanics which could prevent standing and walking are not included in the study. after demographic characteristics are recorded, q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles are measured with a goniometer. the height from the ground of the navicula are calculated by caliper, using the navicular drop test. metatarsal width are also calculated with this device. medial longitudinal arch angle, metatarsal width and nacivular drop tests are performed under weight-bearing and non-weight-bearing conditions.

Eligibility criteria:
inclusion criteria: * healthy university students. * must be able to walk independently. exclusion criteria: * students with chronic sprains. * students who had undergone lower extremity surgery within the last year. * students who use assistive walking devices.

Keywords: foot deformities cluster method kinematic analysis
a safety and tolerability study of jaktinib

Conditions: Myelofibrosis

Summary: this research study is studying a drug called jaktinib as a possible treatment for myelofibrosis.

this study is a phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of jaktinib in patients with pmf or post-pv/et mf and who are relapsed/refractory to a marketed jak inhibitor

Eligibility criteria:
inclusion criteria: * diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia). * relapsed/refractory to a marketed (fda approved) jak inhibitor. * at least 18 years of age. * ecog ps 0, 1, or 2. * expected life expectancy is greater than 24 weeks. exclusion criteria: * any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug. * major surgery or radiation therapy within 28 days prior to initiation of study drug. * with suspected allergies to jaktinib or its excipient. * another clinical trial of a new drug or medical instrument within 3 months before screening. * females who are pregnant, currently breastfeeding, planning to become pregnant. * unable to adopt effective contraceptive methods during the study.
toxicity of treatments for non-tuberculous mycobacterial infections in cancer patients or not

Conditions: Mycobacterium; Cancer; Treatment Side Effects

Summary: non-tuberculous mycobacteria (ntm) are increasingly common and have a poor prognosis: 5-year mortality can reach 40 to 50%, depending on the type of mycobacteria and the immune system of the host involved. cancer patients are at higher risk of infectious morbidity and mortality, which may be due to disease-related immune dysfunction, immunosuppressive effects of chemotherapy, or long-term placement of a vascular catheter. however, data on the treatment of ntm species that cause infections and the disease characteristics of these pathogens in cancer patients are limited despite the growing cancer population worldwide. recently, m. avium infections have been described in patients suffering from cancers (hematological or not), in particular in patients receiving checkpoint inhibitors. although the proportion of m. avium pneumonia in retrospective series is low (0.8-2%), it has been shown that this population is younger, suffers less from sub-pulmonary pathology. (indicating immunosuppression in these patients) but are therefore treated less than non-cancerous subjects. this retrospective study in chu amiens is searching on the number of side effects of ntm treatment in two groups (cancerous and no cancerous) to assess the cause of the decrease of ntm treatment in cancerous patients.


Eligibility criteria:
inclusion criteria: * age equal or more than 18 years18 * patients diagnosed by an infection with non-tuberculous mycobacteria according to ats guidelines. * patients received the ntm treatment. exclusion criteria: * age less than 18 years * patients diagnosed by ntm without treatment. * patients with a positive sample of ntm but without infection. * exclusion of other disorders such as tuberculous.

Keywords: mycobacterium cancer treatment side effects
covid-19 epidemiological surveillance on healthcare workers and patients in a rehabilitation medicine facility

Conditions: SARS-Cov2

Summary: the recent sars-cov2 pandemic has highlighted that the transmission of the virus within health care facilities plays a fundamental role in its propagation and, therefore, in the increase in covid-19 cases registered among patients and healthcare workers. this study, original for the current lack of data on nosocomial transmission mechanisms compared to what happens in the community, proposes to conduct a study in patients, health workers and people in real-life setting. the study will be monocentric and performed at the san raffaele pisana institute in rome, that is able to guarantee the necessary number and the right case-mix that will allow to evaluate any possible correlations between infection and pre-existing disease.

furthermore, hospitals, especially those dedicated to chronic patients, as well as other communities that are not completely closed (such as school and work communities), are also at greater risk of small outbreaks that also affect healthcare professionals. it is therefore necessary to carry out periodic checks on all healthcare professionals who work in healthcare facilities both to ensure their health and avoid the risk of possible contamination and to prevent the possible transmission of infection from the community to the hospital. another essential aspect to prevent infection in such facilities is the control of colonization in admitted patients. negativity from sars-cov2 should be carefully monitored in these patients prior to their placement in different departments. on this basis, the study aims to determine the presence of sars-cov2 by monitoring with serial nasopharyngeal swabs carried out on healthcare professionals working within the facility and on new patients admitted. in order to exclude the possibility of false negatives due to low viral load found in the early stages of infection (incubation time) or any exposure that may occur in the days following the execution of the swab, the study will i provide for the repetition of the swab examination, 3 times, at weekly intervals. in order to verify the correspondence between the presence of igm and igg antibodies against the virus and the positivity to the swabs, the healthcare professionals and patients who undergoing nasopharyngeal swab will be previously subjected to the rapid antibody detection test (prick test for igg and igm).

Eligibility criteria:
inclusion criteria: * patients/participants \> 18 years * subjects who agree with the study signing the informed consent exclusion criteria: * age \<18 years; * pregnancy in progress; * simultaneous participation in another clinical study * ongoing immunosuppressive therapy or during the last month

Keywords: sars-cov2 covid-19 epidemiological surveillance observational study healtcare workers real-life rehabilitation